Continuity Biosciences and Breakthrough T1D Collaborate to Advance NICHE® Cell-Therapy Platform Toward First-in-Human Study
Collaboration supports IND-enabling development and a planned Phase 1/2a first-in-human clinical study in type 1 diabetes CARY, N.C. and NEW YORK, March 24, 2026 /PRNewswire/ -- Continuity Biosciences and Breakthrough T1D, the leading global type 1...
AtomVie Global Radiopharma Supplies First Patient Dose in Radiopharm Theranostics' Phase 1/2a Clinical Study of 177Lu-BetaBart (RV-01)
HAMILTON, ON, Feb. 24, 2026 /PRNewswire/ -- AtomVie Global Radiopharma (AtomVie), a global leading radiopharmaceutical CDMO, announced that it has supplied the successful dosing of the first patient in Radiopharm Theranostics' First-in-Human Phase...